GRI Bio, Inc.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious inflammatory, fibrotic, and autoimmune diseases driven by dysregulated immune responses. The company has no approved products yet and is focused on advancing product candidates such as GRI-0621 and GRI-0803 through preclinical and clinical development toward eventual commercialization.

3.25

3.25

— GRI Bio, Inc.
%
Clinical-stage product candidates0% Drug candidates in preclinical and clinical development, including GRI-0621 and GRI-0803.
Research and development programs100% Discovery and development work aimed at immune-response targets for inflammatory and autoimmune disease.
Future commercial therapies0% Potential marketed products if candidates receive regulatory approval and are launched.

GRI Bio does not yet sell commercial products, so its near-term 'customers' are primarily clinical trial participants,...

  • Clinical development partnersprimary

    CROs, investigators, and trial sites that execute studies and generate data needed for regulatory advancement.

  • Regulatory agenciesprimary

    FDA and other regulators that review safety, efficacy, and manufacturing data before approval.

  • Physicians and specialistssecondary

    Potential future prescribers in immunology, pulmonology, hepatology, and related specialties.

  • Third-party payorssecondary

    Commercial insurers and government programs that would influence adoption and reimbursement after approval.

  • Patients with immune-mediated diseasesecondary

    End users of any approved therapy for inflammatory, fibrotic, or autoimmune disorders.

GRI Bio is headquartered in La Jolla, California and operates as a U.S.-based development-stage biotech company...

  • •Headquartered in La Jolla, California
  • •U.S.-based clinical development and corporate operations
  • •No disclosed country revenue mix because there is no product revenue
  • •Future geographic exposure depends on trial sites and approval markets
  • •Potential commercialization could expand beyond the U.S.

The company’s strategy is to advance GRI-0621, GRI-0803, and future candidates through clinical development, while...

01
Advance lead clinical programsshort-term

The company has no approved products, so value creation depends on generating human efficacy and safety data.

02
Secure additional fundingshort-term

Management disclosed substantial doubt about going concern and expects continued operating losses.

03
Build regulatory and manufacturing readinessmedium-term

Clinical-stage biotech must demonstrate quality, safety, and manufacturability before approval.

GRI Bio faces the core risks of a clinical-stage biotech: development failure, regulatory setbacks, and the need for...

critical

Clinical development failure

GRI-0621, GRI-0803, and other candidates must still prove safety and efficacy in trials.

Scope
Lead programs
Materiality
high
critical

Going concern / financing risk

The company expects continued losses and disclosed substantial doubt about its ability to continue as a going concern.

Scope
Corporate liquidity
Materiality
high
high

Regulatory approval risk

Drug candidates require IND clearance, clinical success, and marketing approval before commercialization.

Scope
FDA and other regulators
Materiality
high
high

Competition from larger biopharma companies

Competitors may have greater capital, broader pipelines, and faster development capabilities.

Scope
Target disease areas such as IPF and autoimmune disorders
Materiality
medium
medium

Cybersecurity and third-party operational risk

The company relies on CROs, clinical sites, and contractors that process sensitive data and run trials.

Scope
Research data and clinical operations
Materiality
medium
Accrued research and development costs
Can shift quarterly R&D expense and liabilities materially
Stock-based compensation
Affects operating loss and comparability across periods
Lease accounting
Impacts balance sheet leverage and occupancy expense timing
Going concern assessment
Important for interpreting financing risk and disclosure quality

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

Zura Bio Ltd

ZURA · Biological Products, (No Diagnostic Substances)

PALISADE BIO, INC.

PALI · Biological Products, (No Diagnostic Substances)

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

Q32 Bio Inc.

QTTB · Pharmaceutical Preparations

: 28/04/2026